ArticleClinical and experimental nephrology2026
Glucocorticoid dose at discharge and the risk of infectious complications and rehospitalization in renal diseases.
Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlucocorticoids have diverse adverse effects, particularly infections that may be severe or opportunistic. Therefore, glucocorticoids are often initiated during hospitalization; however, the optimal glucocorticoid dose at discharge remains uncertain. This study examined whether the discharge dose of glucocorticoids influences infection onset and rehospitalization in patients with renal disease.
methodsThis was a multicenter retrospective cohort study conducted at eight hospitals from 2013 to 2023. Adults initiated on oral prednisolone ≥ 30 mg/day during hospitalization for renal disease were included. The primary outcome was infection within 30 days of discharge; secondary outcomes were rehospitalization for infection and unplanned rehospitalization for any cause. Logistic regression analyses were performed to evaluate primary and secondary outcomes, using glucocorticoid dose and other potential confounding factors as explanatory variables.
resultsAmong 684 patients, 24 (3.5%) developed infections within 30 days, including 17 bacterial (11 pneumonia), 5 fungal, and 2 cytomegalovirus infections; 17 patients (2.5%) required rehospitalization for infection. Overall, 51 patients (7.4%) had unplanned rehospitalization, most often for edema control, primary-disease relapse, or dehydration/electrolyte imbalance. In multivariate logistic regression analysis, oral glucocorticoid dose at discharge was not significantly associated with the primary outcome. No significant differences in infection onset or rehospitalization outcomes were observed across categories of oral glucocorticoid dose at discharge, and similar results were obtained regardless of the cutoff values or categorization strategy used.
conclusionHigher discharge doses of oral glucocorticoids did not increase infection or rehospitalization rates. Discharge timing should therefore be individualized based on overall patient risk rather than glucocorticoid dose alone.
Indexed as
Identifiers
41973359What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.